Insmed Investor Relations Material
Insmed Incorporated is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for patients living with serious and rare diseases. The Company's marketed product ARIKAYCE, or L-Amikacin, is approved in the United States for the treatment of Mycobacterium avium complex lung disease as part of a combination anti-mycobacterial drug regimen for adult patients who are refractory to or intolerant of conventional treatments.
Key slides for Insmed Incorporated
Monopolies and Duopolies: Competition is For Losers?
Explore Peter Thiel's view on why monopolies lead to success and examine the world's top monopolies and duopolies.
27 Feb 2024
Lisa Su: Transforming AMD and Shaping the Semiconductor Industry
Explore Lisa Su's transformative leadership at AMD, including her role in revitalizing the company and her vision for semiconductor innovation.
26 Feb 2024
Klarna's Potential 2024 IPO: From Sequoia to Wall Street
Explore Klarna's journey from a 2005 startup to a fintech giant, its innovative business model, and the anticipation surrounding its 2024 IPO.
23 Feb 2024
🇺🇸 United States